Birks annual sales fall 4%
The Montreal-based company said retail sales were $7.3 million lower than fiscal 2024, primarily due to a decrease in third-party branded jewelry sales. The decrease was partially offset by an increase in branded timepiece sales throughout the retail network.
Comparable store sales decreased by 3.4% in fiscal 2025 compared to fiscal 2024, again mainly due to lower third-party branded jewelry sales, partially offset by an increase in third-party branded timepiece sales and an increase in average sales transaction value.
The company clocked a net loss for fiscal 2025 of $12.8 million, or $0.66 per share, compared to a net loss for fiscal 2024 of $4.6 million, or $0.24 per share.
"Although our net sales and comparable store sales for fiscal 2025 are lower than fiscal 2024, when excluding the effect of third-party jewelry brand movement, comparable store sales are positive year-over-year, as a result of a strong retail performance and product offering particularly in our third-party branded timepieces,' said Jean-Christophe Bédos, president and chief executive officer of Birks Group.
'In fiscal 2025, we opened two new stores under the TimeVallée and Birks brands and continued to benefit from the fiscal 2024 renovations in our Chinook and Laval locations. These initiatives along with our recent announcement of the acquisition of the watch and jewelry business of European Boutique will continue to generate greater sales and contribute to improve our results."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Network
2 hours ago
- Fashion Network
India accuses EU, US of double standard over Russian trade
India has sharply criticised the US and the European Union, saying it is being unfairly singled out by them over its Russian oil purchases when they both trade extensively with Moscow despite the war in Ukraine. India's criticism followed a renewed threat by US President Donald Trump on Monday to raise tariffs on goods from India over its Russian oil purchases, deepening the trade rift between the two countries. In a rare show of unity, Prime Minister Narendra Modi's Bharatiya Janata Party (BJP) and the main opposition Congress on Tuesday condemned Trump's repeated criticism of New Delhi. India's Foreign Ministry said in a statement issued late on Monday that "it is revealing that the very nations criticising India are themselves indulging in trade with Russia". The US embassy and the EU's delegation in New Delhi did not immediately respond to a request for comment. Both the US and EU have sharply scaled back their trade ties with Russia since it launched a full-scale invasion of Ukraine in February 2022. In 2021, Russia was the EU's fifth-largest trading partner, with goods exchange worth 258 billion euros, according to the EU executive European Commission. The sudden rift between India and the US has been deepening since July 31, when Trump announced a 25% tariff on Indian goods being shipped to the US and for the first time threatened unspecified penalties for buying Russian oil. India is one of the biggest buyers of crude from Russia, importing about 1.75 million barrels per day from January to June this year, up 1% from a year ago. India has said it does not support "unilateral sanctions" by the EU. Trade experts say Trump's tariff could badly hurt India's economy. Ajay Srivastava of the New Delhi-based Global Trade Research Initiative said he expected Indian goods exports to the US to fall 30% in the current fiscal year ending March 31, to 60.6 billion dollars from 86.5 billion dollars in the 2025 fiscal year. India's equity benchmarks fell after Trump's renewed threat of harsh tariffs on goods from India. Manish Tewari, a member of parliament and Congress leader, said Trump's "disparaging remarks hurt the dignity and self-respect of Indians". "The time has come to call out this constant bullying and hectoring," he added. BJP Vice President Baijayant Jay Panda quoted Henry Kissinger - the most powerful US diplomat of the Cold War era - in a post on X: "To be an enemy of America can be dangerous, but to be a friend is fatal."
Euronews
2 hours ago
- Euronews
Pfizer earnings strong despite Trump's new 'up to 250%' tariff threat
Pharmaceutical giant Pfizer reported better-than-expected quarterly results on Tuesday and improved its predictions for full-year profits, beating Wall Street expectations. The New York-based company reported second-quarter sales of $14.7 billion (€12.74bn) and earnings per share of $0.51 (€0.44). As of around 16.00 CEST, Pfizer shares were up over 4% at $24.58. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," chairman and CEO Albert Bourla said in a statement. "We continue to be actively engaged with policymakers as we navigate a complicated and rapidly evolving geopolitical environment while also remaining focused on advancing our business," Bourla continued. This despite several policies announced by the current US administration that could hurt drugmakers. In May, US President Donald Trump signed an executive order whereby pharmaceutical companies would be compelled to lower prices based on a "Most Favored Nation" policy. The price-slashing scheme seeks to ban drug companies from selling products in the US at prices above those in other developed countries. In Europe, the comparison becomes complex, as a significant portion pharmaceutical costs are covered by national healthcare or insurance systems, lowering prices for consumers. Experts warned at the time that this could slash their US revenues and affect availability. Even so, the president doubled down on his plans, sending letters last week to 17 drugmakers, calling for concrete steps to cut prices by 29 September. That includes agreeing to provide their full portfolio of existing medicines at no higher than European prices to every single Medicaid patient. On Tuesday, in an interview with CNBC, he announced that tariffs for pharmaceuticals and semiconductors would be coming in "next week". 'We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," he told CNBC.
LeMonde
3 hours ago
- LeMonde
Legal battle erupts over inheritance of former richest man in China
The presumed children of Zong Qinghou, founder of the beverage giant Wahaha who died in February 2024 at the age of 79, have scored an initial victory. On Friday, August 1, the Hong Kong Supreme Court ruled in favor of the three plaintiffs by ordering the freezing of an HSBC account containing $1.8 billion (€1.55 billion), recognizing their rights as presumed beneficiaries of this capital. The plaintiffs claim to be the unacknowledged children from a decades-long secret relationship between the late billionaire and his mistress, Du Jianying, a former Wahaha employee. The case pits them against Zong Fuli, 43 (also known as Kelly Zong), the legitimate daughter of Zong Qinghou and current CEO of Wahaha. The three plaintiffs, two men and one woman, assert that the businessman, an industrial icon in China during the 2000s, promised a month before his death, through a brief handwritten note, to create three offshore trusts to distribute the money evenly. The Hong Kong court ruled in their favor, freezing the Hong Kong account of a British Virgin Islands-based holding company, first managed by Zong Qinghou and then by his legitimate daughter, which was intended to fund these trusts.
